Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint ...

OS Therapies, Inc. , a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has been awarded a presentation slot at ...

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in ...

Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of iopofosine I 131 as a ...

Reports revenue $38.9M, consensus $39.74M. “Following a year marked by tremendous progress, we remain committed to advancing our pipeline of ...

A 16-year-old girl is now free from a growing tumor on her neck after becoming the first patient to undergo surgery with ...

Is chest pain during puberty a cause for concern Understand the stages of breast development and what to expect during this ...

JERSEY CITY, NJ, USA I March 12, 2025 I Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® ...

A new Weill Cornell Medicine and Oregon Health & Science University co-authored study provides critical insight for the development of a vaccine that can more effectively block the spread of ...

WTLQ 97.7 Orgullo Latino is gearing up for its annual Partners in Hope event. A traffic crash on Tuesday evening involving multiple vehicles occurred on Northbound Interstate 75 near Estero. The event ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It ...